未确诊的OSA可能显著影响因COPD入院的城区医院成人患者结局
本研究回顾了2017年5月至2018年7月因COPD急性加重入院的患者,对其中未确诊且未治疗的OSA进行睡眠问卷筛查及高分辨率脉搏血氧监测或便携式睡眠监测。结果显示,在238例完成监测的患者中,46.6%存在OSA,且OSA严重程度越高,30天、90天和180天再入院率及6个月死亡率越高。
要点
- 因COPD急性加重入院的患者中,未确诊OSA的患病率高达46.6%。
- OSA严重程度越高,30天再入院风险及6个月死亡率越高。
- 对COPD入院患者应筛查OSA,以识别再入院和死亡高风险人群。
核心结论
- 因COPD急性加重住院且存在未确诊OSA的患者,其30天、90天和180天再入院率及6个月死亡率均高于无OSA者。
研究设计与样本
- 回顾性研究,纳入2017年5月至2018年7月因COPD急性加重入院、接受睡眠问卷筛查并完成高分辨率脉搏血氧监测或便携式睡眠监测的380例患者中的238例。
主要发现
- 238例完成监测的患者中,111例(46.6%)存在OSA,其中轻度28.6%、中度9.7%、重度8.4%。
- OSA组平均BMI高于无OSA组(33.9 vs 30.3 kg/m2),心力衰竭患病率也更高(19.8% vs 7.1%)。
- 轻度OSA患者30天再入院率32.4%,无OSA患者18.9%,OR为2.05。
- 中度OSA患者30天再入院率60.9%,无OSA患者18.9%,OR为6.68;重度OSA患者30天再入院率70%,无OSA患者18.9%,OR为10.01。
- 90天和180天再入院率同样升高;无OSA患者全因死亡率低于OSA患者(P < .01);OSA越严重,再入院或死亡时间越短(P < .01)。
临床怎么用
- 对因COPD急性加重入院的患者,应考虑使用睡眠问卷筛查未确诊的OSA。
- 筛查阳性者应进一步行高分辨率脉搏血氧监测或便携式睡眠监测以明确诊断。
- 确诊OSA的COPD患者再入院和死亡风险高,可能需要加强随访和干预。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: COPD is the second most common cause of hospital admission in the United States. OSA is a highly prevalent and underdiagnosed condition that may affect the outcome of COPD. RESEARCH QUESTION: We hypothesized that presence of unrecognized and untreated OSA will increase hospital readmissions in patients admitted for COPD exacerbation. STUDY DESIGN AND METHODS: We reviewed patients admitted for COPD exacerbation from May 2017 through July 2018 who were also screened for previously unrecognized and untreated OSA with a sleep questionnaire, and who subsequently underwent a high-resolution pulse oximetry or portable sleep monitoring study. We compared the rates of 30-, 90-, and 180-day readmission or death across OSA categories and compared overall survival in patients with and without OSA. RESULTS: Of 380 patients admitted for COPD exacerbation, 256 were screened for OSA with a sleep questionnaire (snoring, tiredness during daytime, observed apnea, high BP). Of these, 238 underwent an overnight high-resolution pulse oximetry/portable sleep monitoring. Of the 238 total patients, 111 (46.6%) were found to have OSA; 28.6% had mild, 9.7% moderate, and 8.4% severe OSA. Baseline characteristics and demographics were compared between the cohorts of participants with OSA and without OSA and were similar except that patients with OSA had a higher mean BMI (33.9 vs 30.3 kg/m2) and an increased prevalence of heart failure (19.8% vs 7.1%). For patients with COPD and mild OSA, odds of 30-day readmission were 2.05 times higher than for patients without OSA (32.4% vs 18.9%). Additionally, odds of 30-day readmission were 6.68 times higher for patients with moderate OSA vs patients without OSA (60.9% vs 18.9%) and 10.01 times high for patients with severe OSA vs patients without OSA (70% vs 18.9%). Readmission rates were also greater at 90 and 180 days. All-cause mortality was lower for patients without OSA than for patients with OSA (P < .01). The time to hospital readmission or death was shorter with greater OSA severity (P < .01). INTERPRETATION: Patients hospitalized for COPD exacerbation and who have unrecognized OSA; 30-, 90-, and 180-day readmission rates; and 6-month mortality rates are higher than in those without OSA.
引用
- Naranjo M, Willes L, Prillaman BA, et al. Undiagnosed OSA May Significantly Affect Outcomes in Adults Admitted for COPD in an Inner-City Hospital. Chest. 2020. PMID: 32247716. doi:10.1016/j.chest.2020.03.036
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。